Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Exclusive Article Why Wall Street Gave Up on Pfizer—and Why That May Be a MistakeReported by Jeffrey Neal Johnson. Date Posted: 12/31/2025. 
What You Need to Know - Pfizer trades at a historic discount compared to its peers while paying a dividend yield that significantly outperforms the broader market average.
- Strategic acquisitions have established a robust pipeline of next-generation cancer treatments, which are driving growth.
- Management has aggressively re-entered the weight-loss market with new assets, including one that offers a convenient monthly dosing schedule for patients.
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold. Nowhere is this more evident than with Pfizer Inc. (NYSE: PFE). Trading near multi-year lows around $25, the company finishes the year as one of the most unloved assets in the S&P 500. For the casual observer, the pessimism seems justified: revenue from COVID-19 products vanished faster than anticipated, high-profile pipeline candidates failed in clinical trials, and activist investors launched a public campaign against the management team. Still, with the exit of activist investor Starboard Value in November and a realistic reset of financial guidance, the worst of the storm now appears to have passed. Recent geopolitical developments are drawing attention to a larger strategic shift underway — one that some analysts believe could reshape capital flows, industrial priorities, and government spending for years to come.
In a special broadcast, two veteran researchers examine what they describe as a growing national priority driving policy decisions and large-scale investment across energy, technology, and defense-related sectors. They outline why this shift matters for investors and which areas of the market may be most affected as it accelerates. Watch the full broadcast here The bad news is largely priced in, and Pfizer’s stock price has likely found a floor. As we enter 2026, Pfizer presents a rare scenario: a blue-chip company trading at a distressed price, offering a solid dividend yield while it quietly rebuilds its future. The Mathematical Case: Why the Price Is Wrong For value investors, the argument for Pfizer is straightforward. The market is pricing the company as if its earnings will permanently shrink, creating a wide disconnect between the share price and the firm's actual cash-generating capacity. A Historic Valuation Gap Pfizer currently trades at a forward price-to-earnings ratio (P/E) of roughly 8.6x. By comparison, the average pharmaceutical company trades at 15x–20x earnings, and high-growth peers such as Eli Lilly (NYSE: LLY) command substantially higher multiples. When a company is valued at 8.6x earnings, the market is effectively assigning it zero growth. That sets a low bar: Pfizer doesn't need a miracle to see its stock appreciate — it only needs to demonstrate stability. Any positive earnings surprise could prompt multiple expansion, allowing the share price to move closer to industry norms. The Dividend Shield While investors wait for that repricing, they are paid to hold the stock. - Annual Payout: $1.72 per share.
- Current Yield: Approximately 6.9%.
This yield is roughly four times the S&P 500 average and serves as a margin of safety. Even if the stock remains flat through 2026, a near-7% dividend provides a solid baseline return that outpaces most savings accounts and government bonds. Management is supporting the dividend with a $4 billion cost-saving initiative. Cuts to administrative spending and manufacturing optimizations are intended to preserve cash flow and keep those quarterly checks coming. The New Foundation: Oncology Takes the Lead One of Pfizer's strategic answers to the post–COVID growth gap is an aggressive pivot toward oncology. The Guided Missile Technology The centerpiece of Pfizer’s 2023 Seagen acquisition is leadership in Antibody-Drug Conjugates (ADCs). Whereas traditional chemotherapy can damage healthy as well as cancerous cells, ADCs act more like guided missiles: they target specific cancer cells and deliver a toxic payload directly, reducing collateral damage. That technology is already contributing revenue. The Seagen portfolio accounted for approximately $3.4 billion in 2024 and produced $2.75 billion in the first three quarters of 2023, driven in part by strong Padcev sales for bladder cancer. Navigating the Bumps The path has not been entirely smooth. In December 2025, Pfizer reported a safety signal related to Hympavzi, a hemophilia treatment, involving a patient death in a trial extension. While that episode created a temporary market jitter, it has not derailed the broader thesis. The oncology portfolio remains deep — more than 60 programs are in development — and Pfizer recently reinforced the pipeline by licensing a promising bispecific antibody from 3SBio, underscoring ongoing efforts to reload the drug-development pipeline. Catching Up: The Strategy for Weight Loss After an early-2025 setback with its internal GLP‑1 candidate Danuglipron, Pfizer did not abandon the obesity market. In late 2025 the company re-entered the race through two strategic deals. The Injectable Strategy (Metsera) In November, Pfizer acquired Metsera for roughly $7 billion, gaining immediate ownership of MET-097i, a next-generation injectable. Unlike current market leaders that require weekly dosing, this candidate has potential for monthly administration — a notable convenience advantage for patients. The Oral Strategy (YaoPharma) Pfizer also signed a licensing deal with YaoPharma for a small-molecule GLP‑1 candidate, recognizing that many patients prefer oral medications to injections. Why This Matters Pfizer’s current share price implies little or no value for its obesity pipeline. That creates a free option for investors: because expectations are so low, any clinical progress from the Metsera or YaoPharma assets would represent pure upside. Pfizer doesn't need to be first to market; it only needs to capture a meaningful slice of a market that analysts foresee growing toward $100 billion. The Risk/Reward Equation: 2026 Belongs to Value Pfizer enters 2026 as a company in transition but with a reinforced balance sheet. Management has set an achievable revenue floor of approximately $61 billion for the year, which removes a key layer of uncertainty that weighed on the stock. For investors, the math is straightforward. At about $25 per share, downside is cushioned by a healthy dividend and a historically low valuation. The upside could be significant: continued oncology growth or positive results from obesity candidates could trigger a sharp repricing. The unloved stocks of one year often become the standout performers of the next. With the activist saga concluded and the balance sheet stabilized, Pfizer has shifted from a falling knife into a potential core holding for value-oriented portfolios. 2026 may be the year this sleeping giant wakes up.
| 
